“We have already demonstrated scientifically that our process and product is exceptional.” Jason Matuszewski, Chief Executive Officer September 26, 2023 BioStem Technologies (OTC: BSEM) has received Investigational Review Board (IRB) approval for a clinical study that will investigate the utilization and effects of its Vendaje Ⓡ wound care product in diabetic foot ulcers. “We have already demonstrated scientifically that our process and product is exceptional. This study will enhance our...
![BioStem Technologies Takes on Diabetic Foot Ulcers with Innovative Wound Care Product](https://prismmediawire.com/wp-content/uploads/2023/09/Biostem-main-logo--1080x412.png)